GlobalData Report: Novel Therapies to Revitalize the Neuropathic Pain Treatment Market Landscape by 2022
A new report from research and consulting firm GlobalData forecasts the neuropathic pain market value to increase from $2.58 billion in 2012 to $3.53 billion by 2022
A new report from research and consulting firm GlobalData forecasts the neuropathic pain (NP)—covering painful diabetic neuropathy, postherpetic neuralgia and trigeminal neuralgia—market value to increase from $2.58 billion in 2012 to $3.53 billion by 2022, at a compound annual growth rate of 3.19%.
The report cites the expected launch of seven promising NP treatments before 2022—including Daiichi Sankyo’s DS-5565, Convergence’s CNV-2197944, Grünenthal’s Cebranopadol and Impax’s Eladur—and the expected sales of these pipeline therapies to account for 23.8% of the global NP market.
GlobalData believes that there are opportunities for companies to enter the NP market through the development of novel drugs, provided that their product offerings target some of these unmet needs.
*PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
